In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (NASDAQ:IMGN) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (NASDAQ:DVAX) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends ImmunoGen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.